Early Detection of Liver Cancer in Primary Care: A Case-Based Approach for Improving Timely and Equitable Care in Rural and Underserved Communities
February 28, 2023
February 28, 2024
This activity is provided by Talem Health and RME Collaborative.
This online program is recorded content from the live session at Rural Health Clinical Congress Fall 2022 and is co-supported by independent medical education grants from Astellas; Eisai, Inc.; Genentech, a member of the Roche Group; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Organon LLC; Pfizer, Inc.; and Regeneron Pharmaceuticals, Inc. and Sanofi. This activity is supported by independent medical education grants from Eisai, Inc. and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
- Nurses — 0.75 Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.
Over the past two decades, the incidence of hepatocellular carcinoma (HCC)—the most common form of liver cancer—has decreased in urban areas of the United States but steadily increased in rural areas. Primary care clinicians, particularly those serving rural and underserved populations, play a key role in identifying patients who are at risk for HCC and who should undergo surveillance. In this case-based CME/CE activity, expert faculty will lead you through three patient scenarios to discuss risk factors for HCC, guideline recommendations for screening and surveillance, and best practices for collaborating with specialists. Strategies for overcoming barriers, particularly among immigrant and other vulnerable populations, will also be reviewed.
Upon completion of this activity, participants should be better able to:
- Apply guideline recommendations for screening and surveillance to promote early detection and timely, appropriate treatment of HCC
- Employ best practices to support communication and collaboration with specialists in HCC surveillance
- Describe evidence-based strategies for overcoming barriers to HCC screening and surveillance in rural and underserved communities
Ghassan K. Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, NY
Barbara P. Yawn, MD, MSc, FAAFP
Professor of Family and Community Health
University of Minnesota
Joint Accreditation Statement
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.
Disclosure of Conflicts of Interest
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Ghassan K. Abou-Alfa, MD, MBA, has disclosed the following relevant financial relationships: research/grant support from Arcus Biosciences, AstraZeneca Pharmaceuticals, BioNTech, BMS, Celgene Corporation, Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Inc., Puma Biotechnology, Inc., QED Therapeutics, Silenseed, and Yiviva; consultant for Adicet Bio, Inc., Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, Autem Therapeutics, BeiGene, Berry Genomics, Boehringer Ingelheim, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai, Inc., Eli Lilly and Company, Exelixis, Inc., Flatiron Health, Genentech, Inc./Roche, Genoscience Pharma, Helio Genomics, Helsinn Group, Incyte Corporation, Ipsen, Merck & Co., Inc., Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis Pharmaceuticals Corporation, QED Therapeutics, RedHill Biopharma, Rafael Pharmaceuticals, Inc. (now Cornerstone Pharmaceuticals, Inc.), Servier Pharmaceuticals, Silenseed, Sobi, Vector Pharma, and Yiviva.
Barbara P. Yawn, MD, MSc, FAAFP, has no relevant financial relationships to disclose.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME credit, participants must:
- Read the CME/CE information, including the learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or [email protected].